oral once-daily sGC activator
Ph. II for CKD + diabetic neuropathy
from cell-based HTS + opt
J. Med. Chem., Apr. 19, 2021
Bayer AG, Wuppertal, DE
BAY 1101042 (runcaciguat)
The Bayer soluble guanylate cyclase (sGC) activator, BAY 1101042 (runcaciguat), is a once-daily (50 mg), oral clinical candidate in Ph. II for chronic kidney disease and diabetic retinopathy. sGC is…